MAPROTILINE: 209 Adverse Event Reports & Safety Profile
Sharpen Your Memory & Focus Naturally
NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.
209
Total FAERS Reports
30 (14.4%)
Deaths Reported
119
Hospitalizations
209
As Primary/Secondary Suspect
9
Life-Threatening
2
Disabilities
Approved Prior to Jan 1, 1982
FDA Approved
Discontinued
Status
Yes
Generic Available
Active Ingredient: MAPROTILINE HYDROCHLORIDE · FDA Application: 017543 ·
First Report: 19970226 · Latest Report: 20231120
What Are the Most Common MAPROTILINE Side Effects?
#1 Most Reported
Constipation
33 reports (15.8%)
#2 Most Reported
Drug ineffective
31 reports (14.8%)
#3 Most Reported
Off label use
29 reports (13.9%)
All MAPROTILINE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Constipation | 33 | 15.8% | 0 | 24 |
| Drug ineffective | 31 | 14.8% | 0 | 22 |
| Off label use | 29 | 13.9% | 2 | 24 |
| Conjunctivitis | 28 | 13.4% | 0 | 20 |
| Intestinal obstruction | 28 | 13.4% | 0 | 20 |
| Psoriasis | 28 | 13.4% | 0 | 20 |
| Vision blurred | 26 | 12.4% | 0 | 18 |
| Dry eye | 25 | 12.0% | 0 | 20 |
| Mental disorder | 25 | 12.0% | 0 | 20 |
| Tremor | 25 | 12.0% | 1 | 14 |
| Visual impairment | 24 | 11.5% | 0 | 20 |
| Eye irritation | 22 | 10.5% | 0 | 17 |
| Product use in unapproved indication | 20 | 9.6% | 0 | 15 |
| Dizziness | 19 | 9.1% | 1 | 17 |
| Aspiration | 18 | 8.6% | 18 | 14 |
| Rhabdomyolysis | 18 | 8.6% | 0 | 17 |
| Seizure | 17 | 8.1% | 16 | 12 |
| Tachycardia | 17 | 8.1% | 0 | 17 |
| Depressed level of consciousness | 16 | 7.7% | 16 | 12 |
| Depression | 16 | 7.7% | 0 | 15 |
Who Reports MAPROTILINE Side Effects? Age & Gender Data
Gender: 79.8% female, 20.2% male. Average age: 58.2 years. Most reports from: ES. View detailed demographics →
Is MAPROTILINE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2000 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 0 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 0 |
| 2011 | 2 | 0 | 1 |
| 2012 | 2 | 0 | 1 |
| 2013 | 1 | 0 | 0 |
| 2014 | 18 | 4 | 14 |
| 2015 | 8 | 0 | 4 |
| 2016 | 22 | 13 | 18 |
| 2017 | 2 | 0 | 1 |
| 2018 | 8 | 0 | 8 |
| 2019 | 1 | 0 | 0 |
| 2020 | 4 | 0 | 4 |
| 2021 | 10 | 0 | 1 |
| 2022 | 6 | 0 | 0 |
| 2023 | 4 | 0 | 0 |
What Is MAPROTILINE Used For?
| Indication | Reports |
|---|---|
| Depression | 72 |
| Product used for unknown indication | 63 |
| Insomnia | 6 |
| Major depression | 6 |
MAPROTILINE vs Alternatives: Which Is Safer?
MAPROTILINE vs MARALIXIBAT
MAPROTILINE vs MARAVIROC
MAPROTILINE vs MARIBAVIR
MAPROTILINE vs MAVACAMTEN
MAPROTILINE vs MEASLES-MUMPS-RUBELLA VIRUS VACCINE
MAPROTILINE vs MEASLES VIRUS STRAIN ENDERS' ATTENUATED EDMONSTON LIVE ANTIGEN\MUMPS VIRUS STRAIN B LEVEL JERYL LYNN LIVE ANTIGEN\RUBELLA VIRUS STRAIN WISTAR RA 27/3 LIVE ANTIGEN
MAPROTILINE vs MEASLES VIRUS STRAIN ENDERS^ ATTENUATED EDMONSTON LIVE ANTIGEN\MUMPS VIRUS STRAIN B LEVEL JERYL LYNN LIVE ANTIGEN\RUBELLA VIRUS STRAIN WISTAR RA 27/3 LIVE ANTIGEN
MAPROTILINE vs MEASLES VIRUS STRAIN ENDERS' ATTENUATED EDMONSTON LIVE ANTIGEN\MUMPS VIRUS STRAIN B LEVEL JERYL LYNN LIVE ANTIGEN\RUBELLA VIRUS STRAIN WISTAR RA 27/3 LIVE ANTIGEN\VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN
MAPROTILINE vs MEBENDAZOLE
MAPROTILINE vs MEBEVERINE
Official FDA Label for MAPROTILINE
Official prescribing information from the FDA-approved drug label.